305 related articles for article (PubMed ID: 34415791)
1. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V
JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791
[TBL] [Abstract][Full Text] [Related]
2. Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients.
Papautsky EL; Carlson M; Johnson SM; Montague H; Attai DJ; Lustberg MB
Breast Cancer Res Treat; 2022 Jul; 194(1):25-33. PubMed ID: 35568748
[TBL] [Abstract][Full Text] [Related]
3. Medical Oncologists' Knowledge and Perspectives on the Use of Biosimilars in the United States.
Peipert JD; Kaiser K; Kircher S; Greene GJ; Shaunfield S; Hauner K; Cella D; Mroczek DK
JCO Oncol Pract; 2023 Mar; 19(3):e457-e464. PubMed ID: 36623249
[TBL] [Abstract][Full Text] [Related]
4. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
Jackisch C; Lammers P; Jacobs I
Breast; 2017 Apr; 32():199-216. PubMed ID: 28236776
[TBL] [Abstract][Full Text] [Related]
5. Unveiling the Biosimilar Paradox of Oncologists' Perceptions and Hesitations in South Korea: A Web-Based Survey Study.
Shin G; Kim BS; Kim DY; Bae S
BioDrugs; 2024 Mar; 38(2):301-311. PubMed ID: 38212516
[TBL] [Abstract][Full Text] [Related]
6. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
Whalen J
Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
[TBL] [Abstract][Full Text] [Related]
7. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
Wyrwicz L; Rodríguez Sánchez CA; Sánchez-Rovira P; Lewis S; Sandschafer D; San T
Future Oncol; 2024 Apr; 20(13):821-832. PubMed ID: 38305004
[TBL] [Abstract][Full Text] [Related]
8. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
Paplomata E; Nahta R
Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
[TBL] [Abstract][Full Text] [Related]
9. The evolution of biosimilars in oncology, with a focus on trastuzumab.
Nixon NA; Hannouf MB; Verma S
Curr Oncol; 2018 Jun; 25(Suppl 1):S171-S179. PubMed ID: 29910660
[TBL] [Abstract][Full Text] [Related]
10. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
Hara F; Tajima K; Tanabe K
Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
[TBL] [Abstract][Full Text] [Related]
11. Integrating trastuzumab biosimilars and HER2-directed therapies into HER2-positive breast cancer management.
Cuellar S
Am J Manag Care; 2020 Mar; 26(2 Suppl):S32-S40. PubMed ID: 32282173
[TBL] [Abstract][Full Text] [Related]
12. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.
Leung JH; Tai YS; Wang SY; Yip Fion HT; Tsung-Chin H; Chan AL
Breast; 2022 Oct; 65():91-97. PubMed ID: 35870421
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
Liu T; Liu D; Jin Y; Dong M
Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
[TBL] [Abstract][Full Text] [Related]
15. Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients.
AbdulHameed Saeed V; Mohammed NAK
Arch Razi Inst; 2023 Jun; 78(3):981-988. PubMed ID: 38028843
[TBL] [Abstract][Full Text] [Related]
16. Perception of hematologists and oncologists about the biosimilars: A prospective Tunisian study based on a survey.
Hadoussa S; Bouhlel M; Soussi MA; Drira C; Hadoussa M; Khrouf MR
J Oncol Pharm Pract; 2020 Jan; 26(1):124-132. PubMed ID: 31106664
[TBL] [Abstract][Full Text] [Related]
17. [Trastuzumab and its biosimilars].
Sarosiek T; Morawski P
Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China.
Deng W; Hu J; Li M; Yang S; Xie Z; Chen J
Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1117-1126. PubMed ID: 35899310
[TBL] [Abstract][Full Text] [Related]
19. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
Hair J; Maryon T; Lieneck C
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab in Breast Cancer Treatment: The Era of Biosimilars.
Peliçário Vargas B; Sari MHM; Ferreira LM
Anticancer Agents Med Chem; 2022; 22(14):2507-2516. PubMed ID: 35236272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]